Primary Healthcare Disruption And Clinical Trial Supply Risk

By Richard Andrew, senior healthcare supply chain and operations executive

Global healthcare funding reductions are creating tangible risks for clinical trial supply chains, particularly in decentralized regions. Recent policy decisions have resulted in significant reductions in global healthcare aid. While the exact magnitude remains debated, it is estimated that approximately $9 billion in health-related funding has been eliminated from international initiatives. A substantial portion of these reductions has affected programs targeting highly contagious diseases such as HIV, tuberculosis (TB), and malaria.

The consequences of these funding cuts will become increasingly evident over time, particularly in the form of clinical trial delays, site activation challenges, and disruptions to investigational product distribution. One of the most immediate challenges is the realization that restarting suspended healthcare services is neither quick nor straightforward, especially where supply continuity has been disrupted. Reestablishing disease control programs requires rebuilding entire systems of care delivery, along with the infrastructure necessary to support clinical trial execution.

In low-income and emerging countries, this process typically begins with the reestablishment of primary healthcare clinics (PHCs). These facilities provide essential services, including immunizations, maternal care, family planning, and basic disease management, but they also serve as critical infrastructure for clinical trial supply. PHCs function as decentralized sites responsible for investigational product storage, handling, and dispensing. They are locally staffed, cost-effective, and designed to serve defined populations.

Beyond affordability, PHCs are one of the fastest ways to generate measurable public health benefits. By focusing on prevention and early intervention, they reduce disease transmission. As demonstrated during the HIV/AIDS crisis and the COVID-19 pandemic, failure to contain outbreaks locally can lead to rapid global spread due to modern travel.

In addition to their role in delivering essential healthcare services, PHCs are increasingly critical as decentralized sites for clinical research. In emerging markets, these clinics often serve as the frontline infrastructure supporting clinical trials, particularly for infectious diseases. As such, disruptions to PHC systems not only impact public health delivery, they also significantly affect clinical trial supply chains, including investigational product distribution, cold chain integrity, and site-level inventory management.

While addressing disease at its source remains the most effective and economical containment strategy, disruptions at the PHC level also introduce operational risks for clinical trial supply that must be addressed in parallel. Several factors need to be considered:

PHC Reestablishment Requirements

Rebuilding PHCs after prolonged closure requires restarting core systems, with clinical trial supply considerations integrated from the outset:

Infrastructure

• From a clinical supply perspective, infrastructure must support the storage and handling requirements of investigational medicinal products (IMPs). This includes temperature-controlled storage, secure access, backup power systems, and environmental monitoring. Additional considerations may include validated storage conditions, segregation of blinded materials, and space for quarantine or returns. Without these controls, maintaining cold chain compliance and product integrity becomes a major operational risk.

Personnel

• In the context of clinical operations, personnel must also be trained in GCP, product handling, and documentation standards. Proper training ensures compliance with regulatory requirements and reduces risks associated with dosing errors, product mismanagement, or protocol deviations. Training should also account for temperature excursion management, inventory reconciliation, and audit readiness.

Supply Chain

• Supply chain requirements become significantly more complex when supporting clinical trials. In addition to routine medical supplies, PHCs must support the distribution and tracking of investigational products. This includes:
  • cold chain logistics with continuous temperature monitoring
  • inventory control systems for tracking batch numbers and expiration dates
  • site resupply planning based on patient enrollment and dosing schedules.
• In low-resource settings, unreliable transportation networks and limited digital infrastructure further complicate these requirements, increasing the risk of supply disruption, delayed resupply, or protocol noncompliance.

Engagement

• Community engagement directly impacts clinical trial supply planning, as patient recruitment and retention directly impact supply forecasting and site resupply strategies. Unpredictable enrollment can lead to overstocking or shortages of products.

While initial setup is critical, long-term sustainability presents a greater challenge. Unlike one-time start-up funding, maintaining compliant clinical trial supply operations requires consistent annual investment in infrastructure, training, and logistics, often competing with other national priorities.

Illustrative Scenario: Rural PHC Reopening

Reopening a rural clinic after years of closure highlights common challenges, including those that directly impact clinical trial supply and site readiness:

Expected Barriers

• Community hesitation or distrust
• Limited trained workforce, including staff in GCP and investigational product handling
• Poor transportation infrastructure affecting timely product delivery and resupply
• Security concerns, including secure storage of investigational products

Planning Requirements

• Define a cost-effective operating model that accounts for clinical trial supply needs.
• Identify essential services to be delivered, including capability for investigational product storage and dispensing.
• Assess availability of local resources, including cold chain infrastructure and backup power.
• Establish operational processes, including inventory management and documentation standards.

Mitigation Strategies

• Continuous community engagement supports stable enrollment and forecasting accuracy.
• Recruitment incentives ensure trained staff for clinical and supply-related responsibilities.
• Coordinate with local authorities to support logistics, importation, and distribution pathways.
• Align adaptive, needs-based service delivery with patient demand and supply planning.

Only after these steps, including confirmation of supply chain readiness, should implementation begin. Failure to address these factors can delay site activation and disrupt investigational product flows.

Reestablishment Strategy (Short-Term)

Overall Goals

• Implement clinical supply systems for investigational product handling and accountability.
• Establish temperature-controlled logistics and monitoring systems.
• Introduce basic inventory tracking tools (digital where possible) to support traceability and reconciliation.

Infrastructure Rehabilitation

• Repair or replace damaged facilities.
• Restore water, sanitation, and electricity with backup power to support temperature-controlled storage.
• Establish secure, access-controlled storage areas for investigational products, including space for quarantine and returns.

Human Resources

• Rehire local nurses and midwives.
• Expand capabilities to support inventory management, temperature monitoring, and audit readiness.
• Integrate national health system support.
• Train staff in GCP, investigational product handing, and documentation requirements.

Supply Chain Restoration

• Rebuild logistics networks to support timely and reliable investigational product distribution.
• Implement cold chain systems with continuous temperature monitoring and excursion management processes.
• Standardize operational protocols for inventory control, resupply, and documentation.
• Establish clear pathways for product receipt, storage, dispensing, and reconciliation at the site level.

Community Engagement

• Establish local health committees.
• Communicate services clearly to support patient recruitment and retention.
• Provide regular operational updates to maintain trust and engagement.
• Align community outreach with enrollment expectations to support accurate supply forecasting and resupply planning.

Ongoing Support (Long-Term Sustainability)

As PHCs stabilize, establishing clinical trial supply operations alongside care delivery can significantly enhance their joint long-term value. Well-functioning clinics can serve as reliable trial sites, provided they maintain:

• consistent cold chain performance
• accurate inventory and dispensing records
• predictable resupply cycles aligned with patient demand
• compliance with regulatory and audit requirements.

This level of operational consistency strengthens both treatment and research capacity while supporting sustained external investment.

For this reason, successful PHCs are defined by reliability, consistency, and measurable outcomes.

To maintain funding and effectiveness, clinics must implement robust monitoring systems, including:

Performance Indicators

Operational Input Indicators

• Supply availability (fill rate)
• Staff training completion rates, including GCP and investigational product handling
• Infrastructure uptime, particularly for temperature-controlled storage

Operational Output Indicators

• Total patient visits
• Prenatal visits
• Successful deliveries
• Immunization rates (children under 1 year)
• Chronic disease enrollment

Clinical Trial Supply Indicators

• Temperature excursion rate
• Inventory accuracy (physical vs. recorded stock)
• On-time site resupply rate
• Investigational product wastage rate
• Protocol deviation related to supply or handling issues

Financial Accountability

• Quarterly financial reporting tied to operational and supply performance outcomes
• Routine audits and supervision, including GxP compliance where applicable
• Budget tracking aligned with infrastructure, training, and supply chain requirements

Verification Systems

• Infrastructure assessment reports, including storage and monitoring capabilities
• HR and training records, including GCP certification
• Logistics and supply chain reports (shipment, temperature, and inventory data)
• Patient and service registers
• Community health worker activity logs

Summary

PHCs represent the fastest and most cost-effective method for rebuilding healthcare systems. When properly implemented, they deliver essential services across their lifespan and reduce strain on higher-level facilities through preventive care.

Beyond their public health role, PHCs represent a critical but often underutilized component of global clinical trial infrastructure. Strengthening these systems not only improves healthcare access but also enables more resilient, predictable, and efficient clinical trial supply chains. By integrating supply chain best practices — particularly in cold chain management, inventory control, and site resourcing — PHCs can evolve into reliable clinical research hubs, supporting both global health outcomes and the advancement of new therapies.

This merger of basic healthcare and clinical research is attractive to developing countries, many of which lack the financial capacity to sustain these systems independently and rely heavily on external donors.

When funding is available, either internally or externally, continued support depends on financial transparency and demonstrated impact. Strong local governance, whether able to fund ongoing operations, is still vital for ensuring accountability, minimizing resource misallocation, and providing a measurable return on investment.

Despite their obvious value, PHCs face persistent challenges that directly affect clinical supply, including:

• weak forecasting systems
• poor transportation and logistics
• inadequate infrastructure
• insufficient staff training
• funding instability
• governance limitations.

To address these issues, long-term strategies should include:

• adoption of digital health and telemedicine systems to support patient management and supply visibility
• infrastructure modernization to maintain cold chain integrity and secure product storage
• improved transportation networks for reliable investigational product delivery
• enhanced workforce training in GCP, supply handling, and operational protocols
• routine financial and performance reporting tied to both healthcare delivery and clinical trial supply outcomes.

About The Author:

Richard John Andrew is a senior healthcare supply chain and operations executive with over 30 years of leadership across integrated delivery networks, Fortune 500 organizations, government systems, and international markets. He specializes in designing and scaling enterprise supply chain models that align clinical, financial, and operational priorities.